Strategic investments Palo Santo operates in venture capital and private equity with a focus on high-growth opportunities in biotech, drug development, healthcare services, and digital health, presenting opportunities to partner on co-investments, syndications, or fund-of-funds introductions for startups in mental health and psychedelic-assisted treatments.

Mental health focus Their portfolio emphasis on clinically effective, affordable, and accessible mental health and addiction treatments, supported by FDA-aligned evidence, suggests sales opportunities with mental health tech platforms, remote care providers, and specialty clinics seeking scalable solutions.

Evidence-led growth With a rapidly growing evidence base and FDA support for psychedelic-assisted therapies, there is potential to engage Palo Santo on partnerships, licensing, or pilot programs with biotech developers and clinical service providers pursuing innovative, compliant treatment modalities.

Recent wins Recent investment into Beacon Biosignals signals openness to wearable EEG/biomarker technologies; opportunities exist to collaborate on data analytics, digital biomarkers, remote monitoring, and integrated patient monitoring platforms for mental health indications.

Market positioning As a relatively small but active investor with a revenue range of 10-25 million and a global event presence, Palo Santo can be approached for co-investment rounds, strategic partnerships, and advisory roles with firms targeting psychedelic, biotech, and digital health ecosystems.